Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Boehringer Ingelheim

Last Updated: November 28, 2021

DrugPatentWatch Database Preview

LIPIDIL Drug Patent Profile

Email this page to a colleague

« Back to Dashboard

Which patents cover Lipidil, and what generic alternatives are available?

Lipidil is a drug marketed by Abbvie and is included in one NDA.

The generic ingredient in LIPIDIL is fenofibrate. There are forty-two drug master file entries for this compound. Fifty-four suppliers are listed for this compound. Additional details are available on the fenofibrate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Lipidil

A generic version of LIPIDIL was approved as fenofibrate by RHODES PHARMS on May 13th, 2005.

  Free Forever Trial

Drug patent expirations by year for LIPIDIL
Drug Prices for LIPIDIL

See drug prices for LIPIDIL

Recent Clinical Trials for LIPIDIL

Identify potential brand extensions & 505(b)(2) entrants

Chong Kun Dang PharmaceuticalPhase 1
HK inno.N CorporationPhase 1
CJ HealthCare CorporationPhase 1

See all LIPIDIL clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for LIPIDIL
Paragraph IV (Patent) Challenges for LIPIDIL
Tradename Dosage Ingredient NDA Submissiondate
LIPIDIL CAPSULE;ORAL fenofibrate 019304

US Patents and Regulatory Information for LIPIDIL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie LIPIDIL fenofibrate CAPSULE;ORAL 019304-001 Dec 31, 1993 DISCN No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.